Pharmacologic management of gastroesophageal reflux disease
Abstract Pharmacologic management of gastroesophageal reflux disease is based on the control of gastric acid changing the character of refluxate enough to reduce or eliminate symptoms, heal mucosal injury, and improve patients’ quality of life. Therapy principally involves proton pump inhibitors alo...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Katz, Philip O. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2007 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Springer 2007 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Current GERD reports - Philadelphia, Pa. : Current Science Inc., 2007, 1(2007), 2 vom: Juni, Seite 109-113 |
|---|---|
| Übergeordnetes Werk: |
volume:1 ; year:2007 ; number:2 ; month:06 ; pages:109-113 |
| Links: |
|---|
| DOI / URN: |
10.1007/s12171-007-0006-0 |
|---|
| Katalog-ID: |
SPR025399578 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR025399578 | ||
| 003 | DE-627 | ||
| 005 | 20230519110256.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2007 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12171-007-0006-0 |2 doi | |
| 035 | |a (DE-627)SPR025399578 | ||
| 035 | |a (SPR)s12171-007-0006-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Katz, Philip O. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacologic management of gastroesophageal reflux disease |
| 264 | 1 | |c 2007 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Springer 2007 | ||
| 520 | |a Abstract Pharmacologic management of gastroesophageal reflux disease is based on the control of gastric acid changing the character of refluxate enough to reduce or eliminate symptoms, heal mucosal injury, and improve patients’ quality of life. Therapy principally involves proton pump inhibitors along with lifestyle interventions, promotility agents, and $ H_{2} $ receptor antagonists used variably and in decreased frequency. This article reviews the pharmacologic management of gastroesophageal reflux disease emphasizing the optimal use of antisecretory drugs. | ||
| 650 | 4 | |a Omeprazole |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Lansoprazole |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Esomeprazole |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pantoprazole |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Sucralfate |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Levy, Adam H. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current GERD reports |d Philadelphia, Pa. : Current Science Inc., 2007 |g 1(2007), 2 vom: Juni, Seite 109-113 |w (DE-627)564751030 |w (DE-600)2422347-5 |x 1934-9661 |7 nnns |
| 773 | 1 | 8 | |g volume:1 |g year:2007 |g number:2 |g month:06 |g pages:109-113 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12171-007-0006-0 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2190 | ||
| 951 | |a AR | ||
| 952 | |d 1 |j 2007 |e 2 |c 06 |h 109-113 | ||
| author_variant |
p o k po pok a h l ah ahl |
|---|---|
| matchkey_str |
article:19349661:2007----::hraooimngmnogsreohg |
| hierarchy_sort_str |
2007 |
| publishDate |
2007 |
| allfields |
10.1007/s12171-007-0006-0 doi (DE-627)SPR025399578 (SPR)s12171-007-0006-0-e DE-627 ger DE-627 rakwb eng Katz, Philip O. verfasserin aut Pharmacologic management of gastroesophageal reflux disease 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Springer 2007 Abstract Pharmacologic management of gastroesophageal reflux disease is based on the control of gastric acid changing the character of refluxate enough to reduce or eliminate symptoms, heal mucosal injury, and improve patients’ quality of life. Therapy principally involves proton pump inhibitors along with lifestyle interventions, promotility agents, and $ H_{2} $ receptor antagonists used variably and in decreased frequency. This article reviews the pharmacologic management of gastroesophageal reflux disease emphasizing the optimal use of antisecretory drugs. Omeprazole (dpeaa)DE-He213 Lansoprazole (dpeaa)DE-He213 Esomeprazole (dpeaa)DE-He213 Pantoprazole (dpeaa)DE-He213 Sucralfate (dpeaa)DE-He213 Levy, Adam H. aut Enthalten in Current GERD reports Philadelphia, Pa. : Current Science Inc., 2007 1(2007), 2 vom: Juni, Seite 109-113 (DE-627)564751030 (DE-600)2422347-5 1934-9661 nnns volume:1 year:2007 number:2 month:06 pages:109-113 https://dx.doi.org/10.1007/s12171-007-0006-0 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2190 AR 1 2007 2 06 109-113 |
| spelling |
10.1007/s12171-007-0006-0 doi (DE-627)SPR025399578 (SPR)s12171-007-0006-0-e DE-627 ger DE-627 rakwb eng Katz, Philip O. verfasserin aut Pharmacologic management of gastroesophageal reflux disease 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Springer 2007 Abstract Pharmacologic management of gastroesophageal reflux disease is based on the control of gastric acid changing the character of refluxate enough to reduce or eliminate symptoms, heal mucosal injury, and improve patients’ quality of life. Therapy principally involves proton pump inhibitors along with lifestyle interventions, promotility agents, and $ H_{2} $ receptor antagonists used variably and in decreased frequency. This article reviews the pharmacologic management of gastroesophageal reflux disease emphasizing the optimal use of antisecretory drugs. Omeprazole (dpeaa)DE-He213 Lansoprazole (dpeaa)DE-He213 Esomeprazole (dpeaa)DE-He213 Pantoprazole (dpeaa)DE-He213 Sucralfate (dpeaa)DE-He213 Levy, Adam H. aut Enthalten in Current GERD reports Philadelphia, Pa. : Current Science Inc., 2007 1(2007), 2 vom: Juni, Seite 109-113 (DE-627)564751030 (DE-600)2422347-5 1934-9661 nnns volume:1 year:2007 number:2 month:06 pages:109-113 https://dx.doi.org/10.1007/s12171-007-0006-0 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2190 AR 1 2007 2 06 109-113 |
| allfields_unstemmed |
10.1007/s12171-007-0006-0 doi (DE-627)SPR025399578 (SPR)s12171-007-0006-0-e DE-627 ger DE-627 rakwb eng Katz, Philip O. verfasserin aut Pharmacologic management of gastroesophageal reflux disease 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Springer 2007 Abstract Pharmacologic management of gastroesophageal reflux disease is based on the control of gastric acid changing the character of refluxate enough to reduce or eliminate symptoms, heal mucosal injury, and improve patients’ quality of life. Therapy principally involves proton pump inhibitors along with lifestyle interventions, promotility agents, and $ H_{2} $ receptor antagonists used variably and in decreased frequency. This article reviews the pharmacologic management of gastroesophageal reflux disease emphasizing the optimal use of antisecretory drugs. Omeprazole (dpeaa)DE-He213 Lansoprazole (dpeaa)DE-He213 Esomeprazole (dpeaa)DE-He213 Pantoprazole (dpeaa)DE-He213 Sucralfate (dpeaa)DE-He213 Levy, Adam H. aut Enthalten in Current GERD reports Philadelphia, Pa. : Current Science Inc., 2007 1(2007), 2 vom: Juni, Seite 109-113 (DE-627)564751030 (DE-600)2422347-5 1934-9661 nnns volume:1 year:2007 number:2 month:06 pages:109-113 https://dx.doi.org/10.1007/s12171-007-0006-0 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2190 AR 1 2007 2 06 109-113 |
| allfieldsGer |
10.1007/s12171-007-0006-0 doi (DE-627)SPR025399578 (SPR)s12171-007-0006-0-e DE-627 ger DE-627 rakwb eng Katz, Philip O. verfasserin aut Pharmacologic management of gastroesophageal reflux disease 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Springer 2007 Abstract Pharmacologic management of gastroesophageal reflux disease is based on the control of gastric acid changing the character of refluxate enough to reduce or eliminate symptoms, heal mucosal injury, and improve patients’ quality of life. Therapy principally involves proton pump inhibitors along with lifestyle interventions, promotility agents, and $ H_{2} $ receptor antagonists used variably and in decreased frequency. This article reviews the pharmacologic management of gastroesophageal reflux disease emphasizing the optimal use of antisecretory drugs. Omeprazole (dpeaa)DE-He213 Lansoprazole (dpeaa)DE-He213 Esomeprazole (dpeaa)DE-He213 Pantoprazole (dpeaa)DE-He213 Sucralfate (dpeaa)DE-He213 Levy, Adam H. aut Enthalten in Current GERD reports Philadelphia, Pa. : Current Science Inc., 2007 1(2007), 2 vom: Juni, Seite 109-113 (DE-627)564751030 (DE-600)2422347-5 1934-9661 nnns volume:1 year:2007 number:2 month:06 pages:109-113 https://dx.doi.org/10.1007/s12171-007-0006-0 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2190 AR 1 2007 2 06 109-113 |
| allfieldsSound |
10.1007/s12171-007-0006-0 doi (DE-627)SPR025399578 (SPR)s12171-007-0006-0-e DE-627 ger DE-627 rakwb eng Katz, Philip O. verfasserin aut Pharmacologic management of gastroesophageal reflux disease 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Springer 2007 Abstract Pharmacologic management of gastroesophageal reflux disease is based on the control of gastric acid changing the character of refluxate enough to reduce or eliminate symptoms, heal mucosal injury, and improve patients’ quality of life. Therapy principally involves proton pump inhibitors along with lifestyle interventions, promotility agents, and $ H_{2} $ receptor antagonists used variably and in decreased frequency. This article reviews the pharmacologic management of gastroesophageal reflux disease emphasizing the optimal use of antisecretory drugs. Omeprazole (dpeaa)DE-He213 Lansoprazole (dpeaa)DE-He213 Esomeprazole (dpeaa)DE-He213 Pantoprazole (dpeaa)DE-He213 Sucralfate (dpeaa)DE-He213 Levy, Adam H. aut Enthalten in Current GERD reports Philadelphia, Pa. : Current Science Inc., 2007 1(2007), 2 vom: Juni, Seite 109-113 (DE-627)564751030 (DE-600)2422347-5 1934-9661 nnns volume:1 year:2007 number:2 month:06 pages:109-113 https://dx.doi.org/10.1007/s12171-007-0006-0 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2190 AR 1 2007 2 06 109-113 |
| language |
English |
| source |
Enthalten in Current GERD reports 1(2007), 2 vom: Juni, Seite 109-113 volume:1 year:2007 number:2 month:06 pages:109-113 |
| sourceStr |
Enthalten in Current GERD reports 1(2007), 2 vom: Juni, Seite 109-113 volume:1 year:2007 number:2 month:06 pages:109-113 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Omeprazole Lansoprazole Esomeprazole Pantoprazole Sucralfate |
| isfreeaccess_bool |
false |
| container_title |
Current GERD reports |
| authorswithroles_txt_mv |
Katz, Philip O. @@aut@@ Levy, Adam H. @@aut@@ |
| publishDateDaySort_date |
2007-06-01T00:00:00Z |
| hierarchy_top_id |
564751030 |
| id |
SPR025399578 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR025399578</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519110256.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2007 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12171-007-0006-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR025399578</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12171-007-0006-0-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Katz, Philip O.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmacologic management of gastroesophageal reflux disease</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2007</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Springer 2007</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Pharmacologic management of gastroesophageal reflux disease is based on the control of gastric acid changing the character of refluxate enough to reduce or eliminate symptoms, heal mucosal injury, and improve patients’ quality of life. Therapy principally involves proton pump inhibitors along with lifestyle interventions, promotility agents, and $ H_{2} $ receptor antagonists used variably and in decreased frequency. This article reviews the pharmacologic management of gastroesophageal reflux disease emphasizing the optimal use of antisecretory drugs.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Omeprazole</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lansoprazole</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Esomeprazole</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pantoprazole</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Sucralfate</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Levy, Adam H.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Current GERD reports</subfield><subfield code="d">Philadelphia, Pa. : Current Science Inc., 2007</subfield><subfield code="g">1(2007), 2 vom: Juni, Seite 109-113</subfield><subfield code="w">(DE-627)564751030</subfield><subfield code="w">(DE-600)2422347-5</subfield><subfield code="x">1934-9661</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2007</subfield><subfield code="g">number:2</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:109-113</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12171-007-0006-0</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2007</subfield><subfield code="e">2</subfield><subfield code="c">06</subfield><subfield code="h">109-113</subfield></datafield></record></collection>
|
| author |
Katz, Philip O. |
| spellingShingle |
Katz, Philip O. misc Omeprazole misc Lansoprazole misc Esomeprazole misc Pantoprazole misc Sucralfate Pharmacologic management of gastroesophageal reflux disease |
| authorStr |
Katz, Philip O. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)564751030 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1934-9661 |
| topic_title |
Pharmacologic management of gastroesophageal reflux disease Omeprazole (dpeaa)DE-He213 Lansoprazole (dpeaa)DE-He213 Esomeprazole (dpeaa)DE-He213 Pantoprazole (dpeaa)DE-He213 Sucralfate (dpeaa)DE-He213 |
| topic |
misc Omeprazole misc Lansoprazole misc Esomeprazole misc Pantoprazole misc Sucralfate |
| topic_unstemmed |
misc Omeprazole misc Lansoprazole misc Esomeprazole misc Pantoprazole misc Sucralfate |
| topic_browse |
misc Omeprazole misc Lansoprazole misc Esomeprazole misc Pantoprazole misc Sucralfate |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Current GERD reports |
| hierarchy_parent_id |
564751030 |
| hierarchy_top_title |
Current GERD reports |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)564751030 (DE-600)2422347-5 |
| title |
Pharmacologic management of gastroesophageal reflux disease |
| ctrlnum |
(DE-627)SPR025399578 (SPR)s12171-007-0006-0-e |
| title_full |
Pharmacologic management of gastroesophageal reflux disease |
| author_sort |
Katz, Philip O. |
| journal |
Current GERD reports |
| journalStr |
Current GERD reports |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2007 |
| contenttype_str_mv |
txt |
| container_start_page |
109 |
| author_browse |
Katz, Philip O. Levy, Adam H. |
| container_volume |
1 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Katz, Philip O. |
| doi_str_mv |
10.1007/s12171-007-0006-0 |
| title_sort |
pharmacologic management of gastroesophageal reflux disease |
| title_auth |
Pharmacologic management of gastroesophageal reflux disease |
| abstract |
Abstract Pharmacologic management of gastroesophageal reflux disease is based on the control of gastric acid changing the character of refluxate enough to reduce or eliminate symptoms, heal mucosal injury, and improve patients’ quality of life. Therapy principally involves proton pump inhibitors along with lifestyle interventions, promotility agents, and $ H_{2} $ receptor antagonists used variably and in decreased frequency. This article reviews the pharmacologic management of gastroesophageal reflux disease emphasizing the optimal use of antisecretory drugs. © Springer 2007 |
| abstractGer |
Abstract Pharmacologic management of gastroesophageal reflux disease is based on the control of gastric acid changing the character of refluxate enough to reduce or eliminate symptoms, heal mucosal injury, and improve patients’ quality of life. Therapy principally involves proton pump inhibitors along with lifestyle interventions, promotility agents, and $ H_{2} $ receptor antagonists used variably and in decreased frequency. This article reviews the pharmacologic management of gastroesophageal reflux disease emphasizing the optimal use of antisecretory drugs. © Springer 2007 |
| abstract_unstemmed |
Abstract Pharmacologic management of gastroesophageal reflux disease is based on the control of gastric acid changing the character of refluxate enough to reduce or eliminate symptoms, heal mucosal injury, and improve patients’ quality of life. Therapy principally involves proton pump inhibitors along with lifestyle interventions, promotility agents, and $ H_{2} $ receptor antagonists used variably and in decreased frequency. This article reviews the pharmacologic management of gastroesophageal reflux disease emphasizing the optimal use of antisecretory drugs. © Springer 2007 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2190 |
| container_issue |
2 |
| title_short |
Pharmacologic management of gastroesophageal reflux disease |
| url |
https://dx.doi.org/10.1007/s12171-007-0006-0 |
| remote_bool |
true |
| author2 |
Levy, Adam H. |
| author2Str |
Levy, Adam H. |
| ppnlink |
564751030 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s12171-007-0006-0 |
| up_date |
2024-07-03T15:46:26.471Z |
| _version_ |
1803573355057512448 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR025399578</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519110256.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2007 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12171-007-0006-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR025399578</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12171-007-0006-0-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Katz, Philip O.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmacologic management of gastroesophageal reflux disease</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2007</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Springer 2007</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Pharmacologic management of gastroesophageal reflux disease is based on the control of gastric acid changing the character of refluxate enough to reduce or eliminate symptoms, heal mucosal injury, and improve patients’ quality of life. Therapy principally involves proton pump inhibitors along with lifestyle interventions, promotility agents, and $ H_{2} $ receptor antagonists used variably and in decreased frequency. This article reviews the pharmacologic management of gastroesophageal reflux disease emphasizing the optimal use of antisecretory drugs.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Omeprazole</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lansoprazole</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Esomeprazole</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pantoprazole</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Sucralfate</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Levy, Adam H.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Current GERD reports</subfield><subfield code="d">Philadelphia, Pa. : Current Science Inc., 2007</subfield><subfield code="g">1(2007), 2 vom: Juni, Seite 109-113</subfield><subfield code="w">(DE-627)564751030</subfield><subfield code="w">(DE-600)2422347-5</subfield><subfield code="x">1934-9661</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2007</subfield><subfield code="g">number:2</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:109-113</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12171-007-0006-0</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2007</subfield><subfield code="e">2</subfield><subfield code="c">06</subfield><subfield code="h">109-113</subfield></datafield></record></collection>
|
| score |
7.3976994 |